(Nes Ziona, ISRAEL) An Israeli company is developing a new cancer drug which aims to stop cancer from coming back.
Every year millions of people are diagnosed with cancer worldwide. Although modern medicine has made huge progress in treating this disease, what often happens is that the cancer is treated and the patient goes into remission or is even “cured” – but then it becomes a waiting game to see if the cancer comes back. Imagine if there was a new treatment option that would stop cancer from returning!
An Israeli medical team is attempting to do just that, to offer a new treatment with the potential for long-term maintenance – to stop the cancer from coming back.
Vaxil is a clinical stage biotechnology company based in Israel which develops therapeutic vaccines to treat cancer and infectious diseases. Therapeutic vaccines seek to harness the patient’s immune system to attack and destroy cancer cells.
The therapeutic vaccine educates the immune system to seek out and destroy those cells which display cancer “markers” and to leave the healthy cells untouched. This means that the treatment hasvery few side effects, unlike other conventional treatments. This safety profile also means that it is suitable for long-term maintenance therapy.
Vaxil’s lead product, ImMucin, aims to teach the immune system of the cancer patient to attack those cancer cells which display the protein “MUC1″. Since MUC1 appears on 90% of all cancer cellss, ImMucin has a potentially broad application to many different strands of cancer such as lung, breast, kidney, prostate, ovarian, pancreatic and colon cancer – and even to hematological cancers such as leukemia, lymphomas and myeloma.
ImMucin is currently being evaluated in a Phase I/II clinical trial in patients with Multiple Myeloma (a blood cancer). All patients enrolled are in a stage process whereby the disease is coming back after a period of remission.
The clinical trial is being conducted at Hadassah University Hospital in Jerusalem and at the Rambam Medical Center in Haifa. Continue reading.